CDK4 and osteosarcoma: This is followed by an assessment of the basic and clinical findings that are already published in the literature on the CDK4/6 cell cycle regulatory pathway in the context of precision medicine-based molecular profiles in pediatric and AYA osteosarcoma (OS), Ewings Sarcoma (EWS), and rhabdomyosarcoma (RMS).